← Back to Clinical Trials
Recruiting NCT04110067

NCT04110067 Clinical Results of Small Incision Lenticule Extraction (SMILE) for the Correction of High Myopia

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT04110067
Status Recruiting
Phase
Sponsor Suphi Taneri
Condition Myopia
Study Type OBSERVATIONAL
Enrollment 5,000 participants
Start Date 2016-01
Primary Completion 2029-11

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type OBSERVATIONAL
All Conditions
Interventions
Small Incision Lenticule Extraction (SMILE) with Visumax (Carl Zeiss Meditec, Jena)

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 5,000 participants in total. It began in 2016-01 with a primary completion date of 2029-11.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Small Incision Lenticule Extraction (SMILE) was introduced in 2011 using the VISUMAX femtosecond laser (Carl Zeiss Meditec, Jena, Germany). It is designed for correction of myopia and myopic astigmatism. It involves the creation of a corneal tissue disk called lenticule and its extraction through a minimally invasive incision, utilizing only a femtosecond laser. This enables rapid visual recovery with very little discomfort to the patient. This observational case series monitors visual and refractive outcomes of myopic correction for more than -7.75 D. It is to * gather long-term results and refractive stability * detect rare complications or side-effects * evaluate the efficacy in a large number of patients

Eligibility Criteria

Inclusion Criteria: * adults * myopia more than -7.75 D * refractive stability more than 1 year Exclusion Criteria: * corneal irregular astigmatism * ectatic conditions

Contact & Investigator

Central Contact

Suphi Taneri, MD

✉ taneri@refraktives-zentrum.de

📞 +492519877890

Principal Investigator

Suphi Taneri, MD

STUDY CHAIR

Center for Refractive Surgery Muenster

Frequently Asked Questions

Who can join the NCT04110067 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Myopia. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT04110067 currently recruiting?

Yes, NCT04110067 is actively recruiting participants. Contact the research team at taneri@refraktives-zentrum.de for enrollment information.

Where is the NCT04110067 trial being conducted?

This trial is being conducted at Münster, Germany.

Who is sponsoring the NCT04110067 clinical trial?

NCT04110067 is sponsored by Suphi Taneri. The principal investigator is Suphi Taneri, MD at Center for Refractive Surgery Muenster. The trial plans to enroll 5,000 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology